Company Overview and News

 
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update

20h seekingalpha
Glenview Capital Management’s 13F portfolio value decreased from $18.50B to $17.10B this quarter. The number of positions decreased from 58 to 52.

1
U.S. Senate panel to hold hearing on Sprint T-Mobile merger

2018-05-23 reuters
WASHINGTON (Reuters) - A U.S. Senate Committee plans to hold a hearing on June 27 on the proposed $26.5 billion merger of T-Mobile US (TMUS.O) and Sprint Corp (S.N).

 
US Senate panel to hold hearing on Sprint T-Mobile merger - Channel NewsAsia

2018-05-23 channelnewsasia
A U.S. Senate Committee plans to hold a hearing on June 27 on the proposed US$26.5 billion merger of T-Mobile US and Sprint Corp .

1
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-05-22 sec.gov
Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933

1
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-05-22 sec.gov
Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933

 
U.S. stock buybacks in earnings season top $183 bln -TrimTabs

2018-05-22 reuters
NEW YORK (Reuters) - U.S. companies announced $183.4 billion in share buybacks during the most recent earnings season, according to TrimTabs Investment Research.

1
Bought AT&T After Selling Verizon

2018-05-21 seekingalpha
It is too early to pick a clear cut winner in 5G technology at this time.

1
Sprint Stays Relevant for Baby Boomers With Affordable Plan

2018-05-21 zacks
Sprint (S - Free Report) has announced the launch of “Unlimited 55+”, which offers affordable unlimited data plans to customers of age 55 and above. This will bring Sprint on par with T-Mobile US, Inc. (TMUS - Free Report) , which launched an unlimited data plan for senior citizens in August last year. Sprint’s Move to Catch Up With Competitors Sprint, one of the leaders of the U.S telecom industry, has an impressive history of evolving constantly to meet various customer requirements.

4
Tracking David Tepper's Appaloosa Management Portfolio - Q1 2018 Update

2018-05-21 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to David Tepper’s 13F portfolio on a quarterly basis. It is based on Appaloosa Management’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking David Tepper’s Appaloosa Management Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q4 2017.

1
US FCC investigating website flaw that exposed mobile phone locations - Channel NewsAsia

2018-05-19 channelnewsasia
WASHINGTON: The U.S. Federal Communications Commission said on Friday it was referring reports that a website flaw could have allowed the location of mobile phone customers to be tracked to its enforcement bureau to investigate.

1
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-05-18 sec.gov
Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933

1
TMUS / T-Mobile US, Inc. 425 (Prospectus)

2018-05-18 sec.gov
Filed by T-Mobile US, Inc. pursuant to Rule 425 under the Securities Act of 1933

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

22h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

22h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 872590203